THX Pharma (FRA:3VG) EBITDA Margin %: 0.00% (As of Dec. 2025)


FRA:3VG THX Pharma FRA:3VG
30 GF Score
Price €3.22
! 1 Warning Sign
View Full Analysis

What is THX Pharma EBITDA Margin %?

THX Pharma FRA:3VG +1.10% 30 EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus rates FRA:3VG with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 945 Biotechnology companies, THX Pharma ranks worse than 105820% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. THX Pharma's EBITDA for the six months ended in Dec. 2025 was €-2.74 Mil. THX Pharma's Revenue for the six months ended in Dec. 2025 was €0.00 Mil. Therefore, THX Pharma's EBITDA margin for the quarter that ended in Dec. 2025 was 0.00%.

THX Pharma  (FRA:3VG) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

THX Pharma EBITDA Margin % Related Terms

THX Pharma EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for THX Pharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

THX Pharma EBITDA Margin % Chart

THX Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

THX Pharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:3VG vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, THX Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

THX Pharma EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, THX Pharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where THX Pharma's EBITDA Margin % falls into.


FRA:3VG
30GF Score
THX Pharma FRA:3VG
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

THX Pharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

THX Pharma's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-3.792/0
= %

THX Pharma's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-2.74/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
THX Pharma (FRA:3VG) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on THX Pharma and its competitors. According to the industry distribution chart, THX Pharma ranks #999999 out of 945 companies in the Biotechnology industry.
Is THX Pharma's EBITDA Margin % too high?
THX Pharma's current EBITDA Margin % is 0.00%. Based on the distribution chart, THX Pharma ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, THX Pharma has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does THX Pharma's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, THX Pharma ranks #999999 out of 945 companies for EBITDA Margin %. This places THX Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on THX Pharma and its competitors. THX Pharma's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is THX Pharma stock overvalued right now?
THX Pharma (FRA:3VG) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. THX Pharma's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For THX Pharma (FRA:3VG), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

THX Pharma Business Description

Other Exchanges ALTHX:France3VG:Germany
Address 60 avenue Rockefeller, Pepiniere Laennec, Lyon, FRA, 69008
THX Pharma Formerly Theranexus SA is a France based biopharmaceutical company. It is engaged in developing drug candidates to be used in the treatment of central nervous system (CNS) disorders. The company's therapeutics platform is based on simultaneously targeting neurons and glial cells by creating and developing innovative combinations of two distinct drugs: a CNS drug targeting neuronal activity; and a drug targeting glial cells. The drug candidates of the organization are THN102 to treat excessive daytime sleepiness in Parkinson's disease, THN201 for the treatment of neurocognitive disorders in Alzheimer's disease and THN101 for neuropathic pain.
30GF Score

Get the complete analysis for FRA:3VG

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.22
Price